Introduction {#S1}
============

The S100B protein belongs to the S100 family of Ca^2+^-binding signaling proteins which share dual conserved calcium-binding EF- hand motifs. S100 proteins exist exclusively in vertebrates, with 24 members observed in humans \[[@R1]\]. S100B is expressed in astrocytes, Schwann cells, melanocytes, chondrocytes, and adipocytes, among others \[[@R2]\].

Acting as both an intracellular regulator and as a secreted signaling molecule, the S100B protein plays a role in a myriad of cellular processes, including cell proliferation, migration, apoptosis, and differentiation \[[@R3]--[@R7]\].

Consequently, aberrant expression levels of S100B have been implicated in a variety of neurological diseases, cancer, and inflammatory disorders \[[@R8]--[@R14]\]. As S100B has no intrinsic enzymatic activity, its intra and extracellular functions are achieved exclusively by physical interactions to its target molecules in a calcium-dependent manner.

Currently S100B has been reported to interact with a variety of protein targets including the p53 tumor suppressor, CapZ, the RAGE receptor, NDR kinase, neurotensin, cathepsin L inhibitor, Hdm2, Hdm4, protein kinase Cα, ROS-GC1, microtubule-associated tau proteins, melittin, amyloid-β, interleukin-11, the serotonin 5-HT7 receptor, the dopamine D2 receptor and RSK1 \[[@R15]--[@R29]\]. This short perspective focuses on the structural basis of S100B-protein interactions.

Literature Review {#S2}
=================

Structural comparison of S100B-peptide complexes {#S3}
------------------------------------------------

S100B exists primarily as a homodimer of two approximately 11 kDa monomers ([Figure 1A](#F1){ref-type="fig"}), though stable and active tetrameric, hexameric, and octameric forms have been reported \[[@R30]\]. The S100B monomer consists of four α-helices with a β-strand between both helices 1 and 2, and 3 and 4, composing two helix-loop-helix EF-hand motifs connected by a linker region. The C-terminal canonical motif is made up of 12 amino acids involved in Ca^2+^-ion binding, while the N- terminal EF-hand (also termed the "S100-hand" ) contains 14 amino acids, therefore being considered by some as a pseudo-EF-hand because of the extra two amino acids \[[@R31],[@R32]\]. Calcium binding in the N-terminal site I induces limited changes to the structure as a whole (RMSD = 1.472 over 33 atoms), while binding at the C-terminal site II induces a conformational change in helix 3 of up to 90°, leading to the exposure of the binding site for target proteins to access ([Figure 1B](#F1){ref-type="fig"}) \[[@R33],[@R34]\].

S100B interacting protein targets are largely identified by a sequence-based approach using the consensus S100B-interacting sequence (\[K/R\]-\[L/I\]-x-W-x-x-I-L). Pioneered by Ivanenkov et al. \[[@R18]\], the sequence was initially proposed based on phage display library screening for bacteriophage exhibiting Ca^2+−^ dependent interaction with S100B. Employing the consensus sequence in homology searches revealed the actin capping protein (CapZ) as a potential target \[[@R18]\]. Specifically, the peptide TRTKIDWNKILS, referred to as TRTK-12, was chosen due to its significant homology to the consensus sequence. Further investigation revealed Ca^2+−^ dependent interaction between S100B and TRTK-12 or CapZ, leading to the TRTK-12 inhibition of the S100B-CapZ interaction \[[@R18]\]. Subsequent expansion of the S100B-interaction consensus sequence by Wilder et al. to \[K/R\]-\[L/I\]-\[P/S/N/D\]-\[W/L/I\]-\[S/D/L\]- x -\[L/I\]-\[L/F\] allowed for additional protein targets to be identified and analyzed for S100B interaction. S100B has so far been shown to interact with short peptides derived from protein sequences of the p^53^ tumor suppressor, CapZ, the RAGE receptor, NDR kinase, neurotensin, cathepsin L inhibitor, Hdm2, Hdm4, protein kinase Cα, ROS-GC1 \[[@R21],[@R22]\], microtubule-associated tau proteins, melittin, amyloid-β, interleukin-11, the serotonin 5-HT7 receptor, the dopamine D2 receptor and RSK1 \[[@R15],[@R19]--[@R29]\].

The NMR structure solution of the bovine S100B apo-form yielded the first structural view of a S100B protein \[[@R35]\]. Since then, the past 20 years has seen a wealth of information on S100B conformational variability induced by pH \[[@R36]\], temperature \[[@R37]\], and metal ion- dependence \[[@R30],[@R33],[@R38]--[@R41]\]. S100B primarily interacts with its target proteins in the Ca^2+−^bound state \[[@R42]\]. Other targets, such as the giant phosphoprotein AHNAK, are recognized in a Zn^2+−^ dependent manner \[[@R43]\]. Several complexes of Ca^2+−^ bound S100B with short peptides derived from its known targets have been evaluated by NMR and X-ray crystallography, including p^53^, the NDR kinase, the RAGE receptor, RSK1 and CapZ \[[@R19],[@R29],[@R43]--[@R48]\].

The S100B interaction with p^53^ was first proposed by Baudier et al. based on the similarity of the p^53^ PKC-phosphorylation site to that of the myristoylated alanine-rich C kinase substrate (MARCKS) protein \[[@R49]\]. MARCKS phosphorylation is inhibited by EF-hand proteins, including S100B, though the MARCKS PKC-site is not in a good agreement with the S100B consensus sequence \[[@R50]\]. In addition, another region of p^53^ capable of interacting with S100B was identified in the p^53^ oligomerization domain \[[@R17]\]. S100B thus inhibits p^53^ oligomerization \[[@R4]\], as well as phosphorylation by PKC at the p^53^ C- terminus \[[@R49]\]. It was further shown that a peptide derived from the p^53^ carboxy-terminal regulatory domain (CTD) could be phosphorylated by PKC, and this activity could be inhibited by S100B \[[@R16]\]. Such inhibition events consequently reduce the p^53^ transcriptional activity, preventing its stimulation of cell cycle arrest and apoptosis \[[@R4]\].

To counteract the deleterious effects of S100B on p^53^ activity, small molecule screening studies have revealed several inhibitors of the S100B-p^53^ interaction including pentamidine (Pnt) in the form of pentamidine isethionate, an antiprotozoal drug currently approved for treatment of Pneumocystis cariini pneumonia \[[@R51],[@R52]\]. Pnt has been shown to disrupt the S100B-p53 complex, resulting in increased cell apoptosis, p^53^ expression, and decreased cell migration \[[@R53]\]. Phase II clinical trial results revealed a myriad of adverse effects during melanoma treatment with Pnt ([www.clinicaltrials.gov](http://www.clinicaltrials.gov), identifier NCT00729807). Structure solution of the S100B-Pnt complex showed two Pnt molecules bound per monomer, occupying two sites adjacent to the p^53^ binding surface \[[@R40]\]. Further screening studies found several potential inhibitors binding in the hydrophobic cleft of the p^53^ binding site \[[@R52],[@R54]\]. These findings together show three binding sites for drug inhibitors of the S100B-p53 interaction. Currently, the goal is to design inhibitors that span all three sites, likely providing higher affinity and specificity for S100B binding. The Weber group has performed several studies investigating small molecules binding in the three different sites and identifying the so called "FF-gate" composed of Phe87 and Phe88, normally occupying a channel between sites 1 and 2, occluded by a Pnt analog \[[@R52],[@R55]--[@R57]\]. They also identified molecules exclusive to site 3 \[[@R56]\]. With the extensive structural and biochemical data available, a potent inhibitor of the S100B-p53 complex formation seems right around the corner.

Discussion {#S4}
==========

Structural analysis of the complex between S100B and a p^53^-CTD peptide (amino acids 367--388) revealed an induced folding of the peptide, normally unstructured, into an α-helical structure ([Figure 2A](#F2){ref-type="fig"}) \[[@R44]\]. This same induced helical fold is observed in other targets of S100B: RSK1, RAGE, and the NDR kinase ([Figure 2B](#F2){ref-type="fig"}). While all three of these peptides adopt a similar fold when bound to S100B and share a common binding area on the surface of S100B, each target protein does distinguish itself by additional contacts with S100B. In the complex of S100B with an NDR kinase peptide, several hydrophobic contacts are made between NDR side chains and the hydrophobic core of the S100B binding site \[[@R19]\]. In addition, electrostatic interactions are observed between helical side chains from NDR with the linker region of S100B \[[@R19]\]. In the S100B-RSK1 study, Gogl et al. used several peptides to generate co-crystals of the protein-peptide complex, resulting in several crystal structures showing altered binding of peptide(s) to S100B dimers \[[@R29]\]. These interactions have been confirmed by SAXS analysis and NMR NOE assignments \[[@R29]\]. Two of the four tested peptides adopted a helical fold extending through the binding pocket of S100B, with one nearly extending into the unbound S100B subunit of the dimer ([Figure 2B](#F2){ref-type="fig"}). Both structures, however, seem to bypass completely the canonical hydrophobic binding pocket of Ca^2+^-bound S100B, with primarily hydrogen bonding and electrostatic interactions with the S100B linker and surface residues facilitating the interaction. Binding of the RAGE peptide, on the other hand, relies almost exclusively on the S100B hydrophobic binding pocket \[[@R45]\]. With minimal hydrogen bonding and no clear salt bridge formation between the peptide and S100B, the interaction is maintained via burying three hydrophobic residues in the S100B site after the induced helical fold of the peptide ([Figure 2B](#F2){ref-type="fig"}). Indeed, the diversity observed in the interaction surfaces among S100B and its target proteins reveals an extremely large binding surface on S100B allowing for binding a diverse selection of peptide sequences ([Figure 2B](#F2){ref-type="fig"}) \[[@R15]\].

To quantitatively compare the interaction energies of the S100B- peptide complexes, we analyzed the structure models using the Proteins, Interfaces, Structures and Assemblies (PISA) server \[[@R58]\]; the results are summarized in [Table 1](#T1){ref-type="table"}. The results of the PISA analysis compared to the dissociation constants reported for the different complexes reveal a strong correlation between the ΔG of solvation and the Kd values. One exception was the TRTK-12 peptide, though this is likely due to the exceptionally hydrophobic nature of its interface as evidenced by its low ΔG P-value. Indeed, the strongest interaction (Kd = 0.04 ± 0.02 μΜ) coincides with the largest ΔG (−13.4 kcal/mol) in the RSK1-A peptide while the weakest interaction (K~d~ = 23.5 ± 6.6) has the smallest ΔG (−5.0 kcal/mol) in the p^53^ peptide-S100B complex.

This apparent correlation between the *in silico* and *in vitro* quantitative data suggests that known structures can be used as the guidance to identify new S100B targets of high-affinity. As the pool of available S100B-target peptide complex structures grows, it has become clear that the S100B-interaction consensus sequence is largely limiting in that the specific residues involved in interaction with S100B vary greatly between peptide sequences \[[@R15]\]. To reflect this in the search for new S100B targets, specific peptide sequences should be used together with structural homology of the interacting residues. Utilizing this new approach, we identified a new potential target of S100B in the XPB helicase subunit of the general transcription factor TFIIH.

XPB-S100B proposed interaction {#S5}
------------------------------

The Xeroderma pigmentosum complementation group B (XPB) helicase is the largest subunit of the general transcription factor II (TFIIH) complex. XPB plays vital roles in both transcription and nucleotide excision repair \[[@R59]\]. Being an ATP-dependent 3̛-5̛ helicase, the XPB helicase facilitates the opening of the DNA helix during NER to allow for removal of bulky DNA adducts generated as a consequence of UV exposure or chemical therapies for anticancer treatment \[[@R59],[@R60]\]. In addition, the XPB ATPase activity is critical for initiation and promoter melting during transcription \[[@R61]--[@R63]\].

Several structural studies have provided a framework for how XPB functions as a molecular wrench to melt dsDNA both alone \[[@R64],[@R65]\] and in the context of TFIIH \[[@R66]--[@R68]\]. In addition, a high-resolution crystal structure by Hilario et al. provided a model for how the proposed XPB-XPF complex forms to facilitate the 5̛ -incision during NER \[[@R69]\]. Phosphorylation of Ser751 in the C-terminus of XPB acts as a key regulatory site during NER via modulating XPF activity \[[@R70]\]. Furthermore, we notice that the XPB extreme C-terminus shares sequence homology with key residues of the p^53^-CTD, and so we propose that XPB should interact with S100B in a similar fashion to that of the p^53^-S100B complex \[[@R44]\]. Interestingly, such interaction was postulated previously by Lin et al. based on the XPB-p^53^ C-terminal interaction \[[@R4]\]. XPB could block the inhibitory S100B targeting of p^53^ in a competitive manner. A similar mode of regulation was proposed for the S100B-RSK1 complex by Gogl et al. Based on their structural modeling, S100B binding could block ERK2 binding to RSK1, and thus inhibit the phosphorylation of the RSK1 activation loop \[[@R29]\]. This inhibition of RSK1 phosphorylation by S100B, coupled with its inhibition of the RSK1 C-terminal kinase domain, explains how S100B blocks the MAPK signal cascade via RSK1 in malignant melanoma \[[@R29]\]. In a similar fasion, S100B-XPB interactions could have a regulatory role in transcription and/or DNA repair. Specifically, S100B binding to the XPB C-terminal tail could interfere with the phosphorylation of Ser751 of XPB and/or dephosphorylation, resulting in inhibition or stimulation, respectively, of the XPF endonuclease during DNA repair \[[@R70]\]. Alternatively, S100B could physically block the interaction of XPB with the XPF endonuclease complex directly.

Although the amino acid sequences of the XPB and p^53^ extreme C-termini share low sequence homology (\~23% using BLAST), most of the conserved residues in p^53^ form direct contacts with S100B in the S100B-p^53^ peptide complex (PDB entry 1DT7) ([Figures 3A and 3B](#F3){ref-type="fig"}). Specifically, Arg379, His380, Lys382, Met384, Phe385, and Lys386 of the p^53^ peptide show direct contacts with residues of S100B, implying similar interactions in the S100B-XPB complex involving the identical or similar residues Lys771, His772, His774, Leu776, Phe777, and Lys778 of XPB, respectively. Our preliminary results do suggest a stable complex formed between S100B and the XPB C-terminal half consisting of residues 494--782 ([Figure 4](#F4){ref-type="fig"}). During gel filtration chromatography, the peaks of individual XPB and S100B are both shifted to a higher apparent molecular weight when the two proteins are mixed together ([Figure 4A](#F4){ref-type="fig"}). Furthermore, we noticed that a degraded XPB protein (XPBc-Δ) lack of the last 52 residues did not shift, in agreement with our prediction that XPB interacts with S100B via its C-terminal residues. These observations confirm that the sequence conservation between the C-termini of XPB and p^53^ seems sufficient for the interactions with S100B. However, one important discrepancy lies with Leu383 of p^53^, as the corresponding residue of XPB is Pro775. The presence of a proline residue in the XPB sequence would prevent formation of an alpha-helical structure in this region of XPB due to the geometric restrictions of the proline side-chain. This would suggest some changes in the S100B-XPB interface compared to that of S100B-p53 complex. It will be very interesting to further investigate the structural features of the S100B-XPB interface and the biological impact of such an interaction ([Figure 4B](#F4){ref-type="fig"}).

Conclusion and Future Research {#S6}
==============================

In this review, we analyzed the structural basis of the S100B-peptide interactions on available data and literature information. Besides the common binding area shared by all S100B interacting proteins, the additional contacts provided by each target warrant the limitation of sequence only search in identifying new S100B target proteins. We believe that the combinatorial sequence/structure-homology approach for S100B target identification will expand new S100B targets beyond the use of sequence-based searches alone. The identification of the XPB protein as a new S100B target likely reveals a new means of regulating transcription and/or DNA repair through S100B. With the diversity of targets already identified, the processes involving S100B, and other S100 proteins, are likely far more extensive than what we currently know and could have important implications in human health and medicine.
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![S100B dimer and Calcium induced conformational changes. (A) S100B Ca^2+^-bound dimer in ribbon representation (PDB entry 2h61). Monomers are colored in grey and cyan. The C- terminal EF-hand motif of the cyan monomer is colored red, while the N-terminal pseudo-EF-hand motif is colored blue. EF-hand bound Ca^2+−^ ions are shown as yellow spheres. (B) Alignment of apo-S100B (magenta; PDB entry 1b4c) and Ca^2+−^ bound (green; PDB entry 2h61) S100B, shown as in A. Ca^2+−^ induced Helix 3 rearrangement is highlighted with a red oval.](nihms-993685-f0001){#F1}

![Structural comparison of the S100B-peptide interfaces. (A) The S100B-p^53^ peptide complex (PDB entry 1dt7). (Left) S100B is shown as a gray surface with the p^53^ peptide in cartoon representation (red). (Right) Residue properties of the p^53^-binding pocket (white -- hydrophobic, green -- polar, blue -- basic, red -- acidic). (B) Common S100B-peptide interaction surface. (Left) S100B from the NDR-kinase model (PDB entry 1psb) shown as a gray surface with the peptides of NDR (magenta), RAGE (green; PDB entry 4xyn), RSK1 (pink; PDB entry 5csn, blue; PDB entry 5csj, yellow; PDB entry 5csi, cyan; PDB entry 5csf), and TRTK-12 (orange; PDB entry 1mq1) based on superposition of the S100B C- terminus (aa 29--88). (Middle) S100B dimer surface colored accordingly to the bound peptides on the left with common-binding area in black. (Right) Residue properties of the peptide-binding pocket (white -- hydrophobic, green -- polar, blue -- basic, red -- acidic).](nihms-993685-f0002){#F2}

![The XPB-S100B interaction likely resembles the p53- S100B complex. (A) A BLAST sequence alignment of the XPB C- terminus with the p53 negative regulatory domain. Unconservative interacting residues are highlighted in magenta. (B) Stereo-view of the S100B (cyan) complex with p53 (green) interacting region (PDB entry 1DT7) shown in cartoon representation, with residues composing the interface displayed in sticks. Unconservative interacting residues of p53 with XPB are shown with carbons in magenta. The bound calcium ion is shown as a pink sphere.](nihms-993685-f0003){#F3}

![Interaction of XPB with S100B. (A) Gel filtration chromatography profile of the XPB C-terminal half (amino acids 494--782) alone (dashes), S100B dimer alone (dots), or the mixture of the two (solid). The peak shift of the mixed sample compared to those of XPBc and S100B indicates the formation of a stable S100B- XPBc complex. The calibration protein elution positions, demarcated by vertical lines for clarity, were generated from a mix of aldolase (158 kDa, Ald), ovalbumin (44 kDa, Ova), and lactalbumin (14 kDa, Lac) protein standards. (B) SDS-PAGE analysis of the chromatography profiles in (A). Protein bands -- XPBc (494--782); XPBc-Δ (494--730, XPBc degraded during purification \[[@R69]\]); M -- marker, \# -- elution volume fraction.](nihms-993685-f0004){#F4}

###### 

PISA analysis of S100B-peptide complex structures.

  PDB Entry   Peptide                                                                       Interface Area (A2)                      ΔG (kcal/mol)                            ΔG P-value                               K~d~ (ΔM)       Reference
  ----------- -------------------- -------------------------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- --------------- ------------
  1dt7        p53 (367--388)       SHLKSKKGQSTSRHKKLMFKTE                                   480.0^[b](#TFN2){ref-type="table-fn"}^   −7.3^[b](#TFN2){ref-type="table-fn"}^    0.328^[b](#TFN2){ref-type="table-fn"}^   23.5 +/− 6.6    \[[@R44]\]
  1psb        NDR (62--87)         KRLRRSAHARKETEFLRLKRTRLGLE                               689.2^[b](#TFN2){ref-type="table-fn"}^   −9.3^[b](#TFN2){ref-type="table-fn"}^    0.328^[b](#TFN2){ref-type="table-fn"}^   20 +/− 10       \[[@R19]\]
  4xyn        RAGE (54--68)        NTGRTEAWKVLSPQG                                          466.9                                    −8.7                                     0.253                                    2.7 +/− 0.5     \[[@R45]\]
  1mq1        TRTK-12 (265--276)   TRTKIDWNKILS                                             525.7^[b](#TFN2){ref-type="table-fn"}^   −9.9^[b](#TFN2){ref-type="table-fn"}^    0.131^[b](#TFN2){ref-type="table-fn"}^   0.27 +/− 0.03   \[[@R48]\]
  5csf        RSK1-A (683--735)    QSQLSHQDLQLVKGAMAATYSALNSSKPTP QLKPIESSILAQRRVRKLPSTTL   590.4^[c](#TFN3){ref-type="table-fn"}^   −13.4^[c](#TFN3){ref-type="table-fn"}^   0.465^[d](#TFN4){ref-type="table-fn"}^   0.04 +/− 0.02   \[[@R29]\]
  5csi        RSK1-A' (689--735)   QDLQLVKGAMAATYSALNSSKPTPQLKPIES SILAQRRVRKLPSTTL         716.0^[c](#TFN3){ref-type="table-fn"}^   −12.1^[c](#TFN3){ref-type="table-fn"}^   0.491^[d](#TFN4){ref-type="table-fn"}^   1.8 +/− 0.3     \[[@R29]\]
  5csj        RSK1-B (696--735)    GAMAATYSALNSSKPTPQLKPIESSILAQRR VRKLPSTTL                583.9^[c](#TFN3){ref-type="table-fn"}^   −12.2 [c](#TFN3){ref-type="table-fn"}    0.464^[d](#TFN4){ref-type="table-fn"}^   2.5 +/− 0.2     \[[@R29]\]
  5csn        RSK1-C (683--720)    QSQLSHQDLQLVKGAMAATYSALNSSKPTP QLKPIESS                  714.0^[c](#TFN3){ref-type="table-fn"}^   −9.2 [c](#TFN3){ref-type="table-fn"}     0.632^[d](#TFN4){ref-type="table-fn"}^   9.6 +/− 1.4     \[[@R29]\]

The amino acids are color coded as follows based on the PISA analysis: Red -- interfacing residue with S100B; black -- non-interfacing residue; grey -- not modeled in the PDB Entry.

Mean value for both asymmetric S100B monomers of all NMR conformers submitted.

Sum of values for the peptide interactions with both asymmetric S100B monomers.

Mean value for the peptide interactions with both asymmetric S100B monomers
